Hunan Fangsheng Pharmaceutical Co., Ltd. Class A

Hunan Fangsheng Pharmaceutical Co., Ltd. Class A

SSSE:603998
10.54
CNY
+0.38
(+3.74%)
0.74EPS
13.94P/E
4.55BMarket Cap
Apr 23Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.26
1.64
1.09
1.23
1.69
2.45
2.63
3.01
3.58
4.14
3.75
4.11
3.99
4.27
Basic EPS, GAAP
0.23
0.32
0.21
0.16
0.14
0.17
0.19
0.15
0.16
0.66
0.43
0.59
0.7
0.74
Free Cash Flow per Basic Share
0.21
-0.01
0.05
-0.11
-0.27
0.24
-0.09
0.16
- -
0.3
-0.3
0.23
0.64
- -
Dividend per Share
0.02
- -
0.03
0.07
0.02
0.02
0.06
0.16
0.11
0.29
0.4
0.3
0.44
0.52
Book Value per Share
1.12
1.9
2.08
2.14
2.28
2.46
2.59
2.68
2.79
3.16
3.32
3.7
3.9
4.05
Tangible Book Value per Share
0.85
1.7
1.82
1.62
1.7
1.83
1.46
1.57
1.32
1.98
2.08
2.44
2.72
2.85
Basic Weighted Avg Shares
318
253
432
436
426
429
415
425
438
433
434
433
438
440
Sales/Revenue/Turnover
400
416
469
534
721
1,051
1,094
1,279
1,567
1,792
1,629
1,777
1,746
1,877
Operating Margin (%)
21.4
22.75
20.61
14.98
12.83
10.28
9.28
9.56
9.16
11.74
12.55
16
18.65
21.52
Depreciation Expense
14
15
20
27
37
44
54
70
78
78
74
76
81
- -
Net Income, GAAP
73
81
91
70
60
73
79
64
70
286
187
255
306
327
Effective Tax Rate (%)
14.87
14.85
15.52
17.14
19.59
13.43
16.41
22.03
22.99
15.27
11.66
12.64
14.33
17.09
Profit Margin (%)
18.35
19.49
19.35
13.06
8.28
6.94
7.21
4.99
4.47
15.95
11.47
14.36
17.54
17.41
Working Capital
180
567
604
316
231
230
-44
-93
-389
192
-327
-161
-137
-60
LT Debt
- -
- -
- -
- -
- -
- -
30
73
65
299
174
166
23
17
Total Equity
387
842
932
980
1,038
1,113
1,202
1,266
1,304
1,508
1,589
1,735
1,803
1,871
Return on Invested Capital (%)
20.34
13.07
10.3
6.99
5.97
6.63
5.75
3.43
4.23
14.36
7.99
10.59
13.07
14.98
Return on Capital (%)
20.06
12.13
9.01
6.72
5.44
5.92
6.27
5.32
4.69
16.23
9.87
11.89
13.83
15.39
Return on Common Equity (%)
22.56
13.9
10.71
7.69
6.24
7.16
7.24
5.6
5.97
22.11
13.12
16.57
18.38
19.12

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
384
307
199
LT Borrowings
- -
- -
- -
LT Finance Leases
21
19
17
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
439
439
439
Market Capitalization
4,746
3,965
4,549

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,013
1,072
1,039
Cash, Cash Equivalents & STI
254
308
248
Accounts Receivable, Net
250
270
297
Inventories
351
357
354
Total Current Liabilities
1,120
1,130
1,098
Payables & Accruals
- -
- -
- -
ST Debt
384
307
199
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
6.88%
7.43%
3.92%
Free Cash Flow
1,302.71%
2,768.84%
181.67%
Net Income, GAAP
31.37%
67.99%
20.05%
Sales/Revenue/Turnover
15.09%
7.04%
-1.75%
Total Cash Common Dividend
58.95%
39.39%
49.24%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
438
472
438
430
1,777
2025
418
416
- -
493
1,746
2026
463
495
426
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.16
0.15
0.21
0.06
0.59
2025
0.2
0.18
- -
0.09
0.7
2026
0.2
0.25
0.21
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.23
0.01
0.04
0.3
2025
0.07
0.21
- -
0.01
0.44
2026
0.15
0.15
0.2
- -
- -

Company Description

CEO
Xiao Li Zhou
Full Time Employees
1,868
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No. 299, Jiayun Road Changsha HU China 410205
IPO Date
Dec 5, 2014
Business
Hunan Fangsheng Pharmaceutical Co., Ltd. Hunan Fangsheng Pharmaceutical Co., Ltd. (603998.SS) is a China-based pharmaceutical company principally engaged in the research, development, production, and sales of innovative traditional Chinese medicines and chemical drugs. The company manufactures and markets a wide range of products including garcinia cambogia tablets (藤黄健骨片), Xuesetong dispersible tablets and tablets for cardiovascular and cerebrovascular conditions, powerful loquat cream lotion, Ezhemab tablets, Xuanqi bone tablets for orthopedics, children's Jingxing cough tablets and small children's Jingxing cough granules for pediatric respiratory issues, Hesketone dispersible tablets, lysine vitamin B12 granules, cefixime tablets for anti-infection, Jinying capsules for gynecology, Pudilan anti-inflammatory tablets, Dieda Huoxue capsules for traumatology, and Xiaoqinglong capsules; these are offered in forms such as tablets, capsules, granules, oral suspensions, powders, suppositories, powder-injections, and tinctures targeting orthopedic, cardiovascular and cerebrovascular, anti-infection, pediatric, gynecological, respiratory, and other diseases. Founded in 2002 and headquartered in Changsha, Hunan province, the company operates six major production bases across China, focuses on the pharmaceutical manufacturing segment with emphasis on proprietary Chinese medicines, and integrates big health industries and medical services as a high-tech enterprise listed on the Shanghai Stock Exchange since December 5, 2014. Recent developments include its subsidiary Guangdong Fangsheng Rongke Pharmaceutical receiving clinical trial approval for a prostate cancer drug and Ziying for innovative traditional Chinese medicine in 2025, Phase 2 trial success for a stroke treatment showing superior efficacy, acquisition of licensing rights for Xiaoqinglong capsules in February 2025, extension for a blood cholesterol drug production facility, receipt of a drug registration certificate for Indobufen tablets, recognition as a 2025 National Green Factory and ranking in the top 20 Chinese traditional Chinese medicine R&D strengths in June 2025, changes in partnership shares of its merger and acquisition fund in December 2024 without impacting consolidated statements, and cancellation of a 26.65% stake acquisition in Hunan Baijun Hi-Tech Medical Investment Management Co., Ltd. in early 2025.